

Alma Mater Studiorum Università di Bologna
Archivio istituzionale della ricerca

Rare Single Nucleotide and Copy Number Variants and the Etiology of Congenital Obstructive Uropathy:
Implications for Genetic Diagnosis

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Ahram D.F., Lim T.Y., Ke J., Jin G., Verbitsky M., Bodria M., et al. (2023). Rare Single Nucleotide and Copy Number Variants and the Etiology of Congenital Obstructive Uropathy: Implications for Genetic Diagnosis. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 34(6), 1105-1119 [10.1681/ASN.00000000000000132].

Availability:

This version is available at: <https://hdl.handle.net/11585/960170> since: 2024-09-03

Published:

DOI: <http://doi.org/10.1681/ASN.00000000000000132>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

Authors: Ahram, D; Lim, TY; Ke, J; Jin, G; Verbitsky, M; Bodria, M; Kil, B; Chatterjee, D; Piva, S; Marasa, M; Zhang, J; Cocchi, E; Caridi, G; Gucev, Z; Lozanovski, VJ; Pisani, I; Izzi, C; savoldi, g; Gnutti, B; Capone, VP; Morello, W; Guarino, S; Esposito, P; Lambert, S; Radhakrishnan, J; Appel, G; Uy, N; Rao, M; Canetta, P; Bombach, A; Nestor, J; Hays, T; Cohen, D; Finale, C; Wijk, J; La Scola, C; Baraldi, O; Tondolo, F; Di Renzo, D; Jamry-Dziurla, A; Pezzutto, A; Alberti, D; Manca, V; Mitrotti, A; Santoro, D; Conti, G; Martino, M; Giordano, M; Gesualdo, L; Zibar, L; MASNATA, G; Bonomini, M; La Manna, G; Caliskan, Y; RAnghino, A; Kiryluk, K; Marzuillo, P; KrzemieÅ, G; Miklaszewska, M; Lin, F; Montini, G; Scolari, F; Fiaccadori, E; ArapoviÄŸ, A; Saraga, M; McKiernan, J; Alam, S; Zaniw, M; Szczepanska, M; Szmigielska, A; Sikora, P; DroÅ¼dÅ¼, D; Mizerska Wasiak, M; Mane, S; Lifton, RP; Tasic, V; Latos-Bielenska, A; Gharavi, A; Ghiggeri, GM; Materna-Kiryluk, A; Westland, R; Sanna-Cherchi, S

Title: Rare Single Nucleotide and Copy Number Variants and the Etiology of Congenital Obstructive Uropathy: Implications for Genetic Diagnosis

Running title: Genetics of Obstructive Uropathy

Manuscript Type: Original Article - Clinical Research

Manuscript Category:

Funders:

This work was supported by grants (P20 DK116191, RO1 DK103184, and RO1 DK115574) from the National Institutes of Health/NIDDK (to SSC) and a consortium grant 20OC002 from the Dutch Kidney Foundation (to RW). Part of the exome sequencing effort was performed by the Yale Center for Mendelian Genomics (YCMG) funded by the National Human Genome Research Institute (U54 HG006504, to RPL).

Financial Disclosure:

E. Cocchi reports Research Funding: American Society of Nephrology. Z. Gucev reports Consultancy: Novo Nordisk; Advisory or Leadership Role: Novo Nordisk; and Speakers Bureau: Takeda. S. Guarino reports Speakers Bureau: Ferring. J. Radhakrishnan reports Consultancy: Reistone Biopharma, Sanofi Genzyme, Equillium Bio, Aurinia Pharmaceuticals, Reata Pharmaceuticals, Travers Therapeutics, Angion Biomedica, Ani Pharmaceuticals, Novartis, Goldfinch Bio, Chinook; Research Funding: Travers Therapeutics, Bayer, Goldfinch Bio, Vertex pharmaceuticals; Honoraria: Reistone Biopharma, Sanofi Genzyme, Equillium Bio, Aurinia Pharmaceuticals, Reata Pharmaceuticals, Travers Therapeutics, Angion Biomedica, Ani Pharmaceuticals, Novartis, Goldfinch Bio, Chinook; and Advisory or Leadership Role: Kidney International, Kidney International Reports. G. Appel reports Consultancy: Aurinia, Bristol Myers Squibb, EMD Serono, Genentech, Genzyme-Sanofi, E. Lilly, Merck, Pfizer, Mallinkrodt, Omeros, Achillion, Alexion, Reata, Travers therapeutics, chemocentryx, Glaxo-Smith-Kline, Vertex therapeutics, Novartis, Apellis, Chinook, Arrowhead; Research Funding: Sanofi-Genzyme, Mallinkrodt, Reata, Genentech-Roche, Chemocentryx, achillion-alexion, Apellis, Goldfinch, Novartis, Equillium; Honoraria: Aurinia, Glaxo Smith Kline; Patents or Royalties: UpToDate; Advisory or Leadership Role: UpToDate - Editorial Board, Med Advisory board for Alexion, BM Squib, Roche, Genentech, Sanofi, Reata, Aurinia, Lilly, Apellis, Alexion-Achillion, Glaxo-Smith -Kline, Chinook, Arrowhead; and Speakers Bureau: Aurinia - lectures on Lupus Nephritis, GSK - lectures on

Lupus Nephritis. P. Canetta reports Consultancy: Otsuka, Travers, Chinook, Novartis; and Research Funding: Calliditas, Travers, Novartis. A. Bomback reports Consultancy: Chemocentryx, Novartis, Otsuka, Silence Therapeutics, Visterra, Catalyst, Q32, Apellis; and Honoraria: UpToDate, Travers, Novartis, Principio, Alexion, Aurinia, Calliditas, Glaxo Smith Kline. D. Cohen reports Consultancy: Alexion - International aHUS Registry - Scientific Advisory Board; Research Funding: Natera, CSL Behring; Honoraria: ITB Pharmaceuticals, Veloxis, Novartis; Advisory or Leadership Role: Alexion - aHUS International Registry - Scientific Advisory Board; and Other Interests or Relationships: American Society of Transplantation – member, The Transplantation Society – member, NY Society of Nephrology - member. D. Santoro reports Honoraria: Alexion, Travers Therapeutics, Viphor Pharma, Fresenius; and Advisory or Leadership Role: George Clinical. L. Gesualdo reports Consultancy: SANDOZ, SANOFI, BAXTER, MUNDIPHARMA, ESTOR, PHARMADOC, RETROPHIN, TRAVERE, ASTRAZENECA, GSK, NOVARTIS, CHINOOK, ROCHE, MEDTRONIC; Research Funding: ABIONYX, SANOFI; Honoraria: FRESENIUS, ESTOR, WERFEN, ASTELLAS, ASTRAZENECA, TRAVERE; Patents or Royalties: McGraw-Hill Education (Italy) Srl; and Advisory or Leadership Role: NDT Journal, Journal of Nephrology, Board of Directors (SIN, RPS, ERA-EDTA). L. Zibar reports Honoraria: Medison Pharma, and Servier. M. Bonomini reports Consultancy: Astellas; Research Funding: Iperboreal Pharma, Hexal; Advisory or Leadership Role: GSK, Travers Therapeutics; and Speakers Bureau: Astellas, and Nipro. G. La Manna reports Consultancy: Alexion, Astellas, Eli-Lilly, Hansa-Biopharma, Vifor, and Travers therapeutics. A. Ranghino reports spouse works in Diatech Pharmacogenetics s.r.l. K. Kiryluk reports Consultancy: Calvariate, HiBio; and Research Funding: AstraZeneca, Vanda, Bioporto, Aevi Genomics, Visterra. M. Miklaszewska reports Honoraria: Medycyna Praktyczna - Pediatria. F. Lin reports Honoraria: lectures and seminars in academic institutions; and Advisory or Leadership Role: JASN editorial board. G. Montini reports Consultancy: Bayern, Alnylam, Kiowa Kyrin, Chiesi Farmaceutici, Sandoz; and Advisory or Leadership Role: Bayern, Alnylam. E. Fiaccadori reports Consultancy: Astellas, Nipro, BBraun, Astra Zeneca; and Other Interests or Relationships: Member Italian Society of Nephrology, Member European Society of Parenteral & Enteral

Nutrition. M. Zaniew reports Honoraria: Alnylam. M. Szczepanska reports Research Funding: FMS in Zabrze, SUM in Katowice; Honoraria: Swixx, Roche, Baxter; and Other Interests or Relationships: ESPN, ERA-EDTA, Polish Society for Pediatrics, Polish Society for Pediatric Nephrology. D. Drozd reports Research Funding: Roche. M. Mizerska-wasiak reports Other Interests or Relationships: European Society Pediatric Nephrology- member, European Renal Association-European Dialysis Transplantation Association -member. A. Gharavi reports Consultancy: Astra Zeneca Center for genomics research, Goldfinch Bio; Actio biosciences, Novartis; Travere; Ownership Interest: Actio; Research Funding: Renal Research Institute, Natera; Honoraria: Sanofi, Alnylam; and Advisory or Leadership Role: Editorial board: JASN and Journal of Nephrology. R. Westland reports Research Funding: Dutch Kidney Foundation (20C002). S. Sanna-Cherchi reports Research Funding: NIH/NIDDK, DoD; Honoraria: Travere Therapeutics; and Advisory or Leadership Role: Editorial Boards with No royalties. S. Lambert reports Ownership Interest: stock in Abbvie and Abbott. D. Ahram reports Employer: Quest Diagnostics. D. Chatterjee reports Employer: H.C. Wainwright & Co., and Citibank; and Patents or Royalties: spouse has a patent with Columbia University Medical Center, not with any for-profit Company. R. Lifton reports Consultancy: Genentech; Ownership Interest: Roche, Merck; and Advisory or Leadership Role: Roche Board of Directors, and Genentech Board of Directors. J. Mckiernan reports Consultancy: miR Scientific; and Advisory or Leadership Role: miR Scientific. All remaining authors declared no competing interests.

Because Ali Gharavi is an editor of the Journal of the American Society of Nephrology, he was not involved in the peer review process for this manuscript. A guest editor oversaw the peer review and decision-making process for this manuscript.

Study Group/Organization Name:

Study Group Members' Names:

Total number of words:3166

Abstract:

Background: Congenital obstructive uropathy (COU) is a common cause of developmental defects of the urinary tract, with heterogeneous clinical presentation and outcome. Genetic analysis has the potential to elucidate the underlying diagnosis and help risk stratification.

Methods: We performed a comprehensive genomic screen of 733 independent COU cases, which consisted of individuals with ureteropelvic junction obstruction (UPJO; n=321), ureterovesical junction obstruction/congenital megaureter (UVJO; n=178), and congenital hydronephrosis not otherwise specified (COU-NOS; n=234). We identified pathogenic single nucleotide variants (SNVs) in 53 (7.2%) cases and genomic disorders in 23 (3.1%) cases. No significant differences in the overall diagnostic yield among COU sub-phenotypes nor pathogenic SNVs in several genes were associated with any of the three categories.

Discussion: Although COU may appear phenotypically heterogeneous, COU phenotypes are likely to share common molecular bases. However, mutations in *TNXB* were more often identified in COU-NOS cases, demonstrating the diagnostic challenge in discriminating COU from hydronephrosis secondary to vesicoureteral reflux, particularly when diagnostic imaging is incomplete. Pathogenic SNVs in only six genes were found in more than one individual, supporting high genetic heterogeneity. Finally, convergence between data on SNVs and genomic disorders suggest *MYH11* as a dosage-sensitive gene possibly correlating with severity of COU.

Conclusion: We established a genomic diagnosis in 10.0% of COU individuals. The findings underscore the urgent need to identify novel genetic susceptibility factors to COU to better define the natural history of the remaining 90% of cases without a molecular diagnosis.

Significance Statement:

Congenital obstructive uropathy (COU) is a prevalent human developmental defect with highly heterogeneous clinical presentations and outcomes. Genetics may refine diagnosis, prognosis, and treatment, but the genomic architecture of COU is largely unknown. Comprehensive genomic screening study of 733 cases with three distinct COU sub-phenotypes revealed disease etiology in 10.0% of them. We detected no significant differences in the overall diagnostic yield among COU sub-phenotypes, with characteristic variable expressivity of several mutant genes. Our findings therefore may legitimize a “genetic first” diagnostic approach for COU, especially when burdening clinical and imaging characterization is not complete or available.

Journal of the American Society of Nephrology Publish Ahead of Print

DOI: 10.1681/ASN.0000000000000132

Rare Single Nucleotide and Copy Number Variants and the Etiology of Congenital Obstructive Uropathy: Implications for Genetic Diagnosis

Dina F Ahram PhD^{1*}, Tze Y Lim MSc^{1*}, Juntao Ke PhD^{1*}, Gina Jin BS^{1*}, Miguel Verbitsky PhD¹, Monica Bodria MD², Byum Hee Kil BS¹, Debanjana Chatterjee PhD¹, Stacy E Piva BS¹, Maddalena Marasa MD¹, Jun Y Zhang PhD¹, Enrico Cocchi MD¹, Gianluca Caridi BS^{2,3}, Zoran Gucev MD⁴, Vladimir J Lozanovski MD^{4,5}, Isabella Pisani MD⁶, Claudia Izzi MD⁷, Gianfranco Savoldi MD⁸, Barbara Gnutti MS⁸, Valentina P Capone MD^{1,9}, William Morello MD⁹, Stefano Guarino MD¹⁰, Pasquale Esposito MD^{11,12}, Sarah Lambert MD¹³, Jai Radhakrishnan MD¹, Gerald B Appel MD¹, Natalie S Uy MD¹⁴, Maya K Rao MD¹, Pietro A Canetta MD¹, Andrew S Bomback MD¹, Jordan G Nestor MD¹, Thomas Hays MD, PhD¹⁵, David J Cohen MD¹, Carolina Finale NA¹⁶, Joanna A E

van Wijk MD, PhD¹⁷, Claudio La Scola MD¹⁸, Olga Baraldi MD¹⁹, Francesco Tondolo MD¹⁹, Dacia Di Renzo PhD²⁰, Anna Jamry-Dziurla BS²¹, Alessandro Pezzutto MD²², Valeria Manca MD²³, Adele Mitrotti MD^{1,24}, Domenico Santoro MD²⁵, Giovanni Conti MD²⁶, Marida Martino MD²⁷, Mario Giordano MD²⁷, Loreto Gesualdo MD²⁴, Lada Zibar MD, PhD^{28,29}, Giuseppe Masnata MD²³, Mario Bonomini MD²², Daniele Alberti³⁰, Gaetano La Manna MD³¹, Yasar Caliskan MD³², Andrea Raghino MD¹⁶, Pierluigi Marzuillo MD¹⁰, Krzysztof Kiryluk¹, Grażyna Krzemień MD³³, Monika Miklaszewska MD³⁴, Fangming Lin¹⁴, Giovanni Montini MD^{9,35}, Francesco Scolari MD³⁶, Enrico Fiaccadori MD⁶, Adela Arapović^{37,38}, Marijan Saraga MD^{37,38}, James McKiernan³⁹, Shumyle Alam MD^{39,40}, Marcin Zaniew MD⁴¹, Maria Szczepańska MD⁴², Agnieszka Szmigielska MD³³, Przemysław Sikora MD⁴³, Dorota Drożdż MD³⁴, Malgorzata Mizerska-Wasiak MD³³, Shrikant Mane PhD⁴⁴, Richard P Lifton MD, PhD⁴⁴, Velibor Tasic MD⁴, Anna Latos-Bielenska MD²¹, Ali G Gharavi MD¹, Gian Marco Ghiggeri MD^{2,3}, Anna Materna-Kiryluk MD²¹, Rik Westland MD, PhD¹⁷, Simone Sanna-Cherchi MD¹

¹Department of Medicine, Division of Nephrology, Columbia University, New York, New York, USA

²Division of Nephrology and Renal Transplantation, IRCCS Istituto Giannina Gaslini, Genoa, Italy

³Laboratory on Molecular Nephrology, IRCCS Istituto Giannina Gaslini, Genoa, Italy

⁴Medical Faculty of Skopje, University Children's Hospital, Skopje, Macedonia

⁵Department of General, Visceral and Transplant Surgery, University Hospital Heidelberg, Germany

⁶Unità Operativa Nefrologia, Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Medicina e Chirurgia, Università di Parma, Parma, Italy

⁷Division of Nephrology and Department of Obstetrics and Gynecology, ASST Spedali Civili of Brescia, Brescia, Italy

⁸Medical Genetics Laboratory, ASST-Spedali Civili, Brescia, Italy

⁹Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, via della Commenda 9, Milan, Italy

¹⁰Department of Woman and Child and of General and Specialized Surgery, Università degli Studi della Campania "Luigi Vanvitelli", Naples, 80138, Italy

- ¹¹Department of Internal Medicine, University of Genoa, Genova, Italy.
- ¹²Unit of Nephrology, IRCCS San Martino Polyclinic Hospital, Genoa, Italy
- ¹³Yale School of Medicine/Yale New Haven Health System, New Haven, CT, USA
- ¹⁴Department of Pediatric, Division of Pediatric Nephrology, Columbia University Irving Medical Center NewYork-Presbyterian Morgan Stanley Children's Hospital in New York, NY, USA
- ¹⁵Department of Pediatrics, Division of Neonatology, Columbia University, New York, NY, USA
- ¹⁶Nephrology, Dialysis and Renal Transplantation Unit, Azienda Ospedaliera Universitaria Ospedali Riuniti Umberto I, Lancisi, Salesi of Ancona, Ancona, Italy
- ¹⁷Department of Pediatric Nephrology, Emma Children's Hospital, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
- ¹⁸Department of Pediatrics, Nephrology and Dialysis Unit, Azienda Ospedaliero Universitaria Sant'Orsola-Malpighi, Via Massarenti 11, Bologna, 40138, Italy
- ¹⁹Nephrology, Dialysis and Renal Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, Bologna, Italy
- ²⁰Pediatric Surgery of "G. d'Annunzio" University of Chieti-Pescara and "Spirito Santo" Hospital of Pescara, Italy
- ²¹Polish Registry of Congenital Malformations, Chair and Department of Medical Genetics, University of Medical Sciences, 61-701 Poznan, Poland
- ²²Department of Medicine, Nephrology and Dialysis Unit, SS Annunziata Hospital, "G. d'Annunzio" University, Chieti, Italy
- ²³Department of Pediatric Urology, Azienda Ospedaliera Brotzu, Cagliari, Italy
- ²⁴Department of Emergency and Organ Transplantation, Section of Nephrology, University of Bari, Bari, Italy
- ²⁵Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
- ²⁶Department of Pediatric Nephrology, Azienda Ospedaliera Universitaria "G. Martino", Messina, Italy
- ²⁷Pediatric Nephrology and Dialysis Unit, Pediatric Hospital "Giovanni XXIII", Bari, Italy
- ²⁸Department of Nephrology, University Hospital Merkur, Zagreb, Croatia

- ²⁹Faculty of Medicine University Josip Juraj Strossmayer in Osijek, Osijek, Croatia
- ³⁰Pediatric Surgery, University of Brescia, Brescia, Italy
- ³¹IRCCS Azienda Ospedaliera di Bologna, Nephrology, Dialysis and Kidney Transplant Unit, St. Orsola University Hospital, Via Massarenti 9, Bologna, 40100, Italy
- ³²Division of Nephrology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA
- ³³Department of Pediatrics and Nephrology, Medical University of Warsaw, Warsaw, Poland
- ³⁴Department of Pediatric Nephrology and Hypertension, Jagiellonian University Medical College, Krakow, Poland
- ³⁵Department of Clinical Sciences and Community Health, Giuliana and Bernardo Caprotti Chair of Pediatrics, University of Milano, Milano, Italy
- ³⁶Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Division of Nephrology and Dialysis, University of Brescia and ASST Spedali Civili of Brescia, Brescia, Italy
- ³⁷Department of Pediatrics, University Hospital of Split,, Split, Croatia
- ³⁸School of Medicine, University of Split, Split, Croatia
- ³⁹Department of Urology, Columbia University Irving Medical Center, New York, NY, USA
- ⁴⁰Division of Pediatric Urology, MUSC Health-University Medical Center, Charleston, SC, USA
- ⁴¹Department of Pediatrics, University of Zielona Góra, Zielona Góra, Poland
- ⁴²Department of Pediatrics, FMS in Zabrze, Medical University of Silesia, Katowice, Poland
- ⁴³Department of Pediatric Nephrology, Medical University of Lublin, Lublin, Poland
- ⁴⁴Yale Center for Mendelian Genomics (YCMG), New Haven, CT, USA
- *These authors contributed equally

WORD COUNT

Abstract: 241 words

Text: words (including statement, excluding methods)

ADDRESS CORRESPONDENCE TO:

Simone Sanna-Cherchi, M.D., Associate Professor of Medicine, Division of Nephrology, Columbia University Vagelos College of Physicians and Surgeons, 1150 Street Nicholas Avenue, Russ Berrie Pavilion #412D, New York, New York 10032, USA. Tel: 212-851-4925. Fax: 212-851-5461. E-mail: ss2517@cumc.columbia.edu.

Short running title: Genetics of obstructive uropathy

ABSTRACT

Background: Congenital obstructive uropathy (COU) is a common cause of developmental defects of the urinary tract, with heterogeneous clinical presentation and outcome. Genetic analysis has the potential to elucidate the underlying diagnosis and help risk stratification.

Methods: We performed a comprehensive genomic screen of 733 independent COU cases, which consisted of individuals with ureteropelvic junction obstruction (UPJO; n=321), ureterovesical junction obstruction/congenital megaureter (UVJO; n=178), and congenital hydronephrosis not otherwise specified (COU-NOS; n=234). We identified pathogenic single nucleotide variants (SNVs) in 53 (7.2%) cases and genomic disorders in 23 (3.1%) cases. No significant differences in the overall diagnostic yield among COU sub-phenotypes nor pathogenic SNVs in several genes were associated with any of the three categories.

Discussion: Although COU may appear phenotypically heterogeneous, COU phenotypes are likely to share common molecular bases. However, mutations in *TNXB* were more often identified in COU-NOS cases, demonstrating the diagnostic challenge in discriminating COU from hydronephrosis secondary to vesicoureteral reflux, particularly when diagnostic imaging is incomplete. Pathogenic SNVs in only six genes

were found in more than one individual, supporting high genetic heterogeneity. Finally, convergence between data on SNVs and genomic disorders suggest *MYH11* as a dosage-sensitive gene possibly correlating with severity of COU.

Conclusion: We established a genomic diagnosis in 10.0% of COU individuals. The findings underscore the urgent need to identify novel genetic susceptibility factors to COU to better define the natural history of the remaining 90% of cases without a molecular diagnosis.

ACCEPTED

INTRODUCTION

Obstructive uropathy is caused by structural or functional defects of the urinary tract that constrain urinary flow from the kidneys to the bladder^{1,2}. Congenital hydronephrosis is the main presenting indicator for urinary tract obstruction, which is diagnosed in 2 to 29 cases per 10,000 live births³. Because hydronephrosis is clinically silent in most cases and neonates and children do not undergo screening by imaging studies, this incidence is vastly underestimated. In humans, kidney and urinary tract development starts at the fifth gestational week, when protrusion of the ureteric bud into the metanephric mesenchyme enables the formation of a patent ureter and fetal urinary flow from the metanephros to the embryonic bladder^{4,5}. At the same time, the bladder and urethra are formed from the urogenital sinus^{6,7}. Unilateral or bilateral perturbations in these tightly regulated processes may therefore affect every level of the kidney and urinary tract, resulting in obstructive uropathy categorized into four main phenotypic groups based on their anatomical localization: (1) uretero-pelvic junction obstruction (UPJO), (2) uretero-vesical junction obstruction (UVJO) leading to a (non-refluxing) megaureter, (3) dysfunction of the bladder e.g. caused by either neurogenic (e.g. spina bifida) or non-neurogenic causes, and, (4) lower urinary outflow tract obstruction caused by posterior urethral valves (PUV), urethral atresia or prolapsing ureterocele^{8,9}. Based on a clinical perspective, UPJO and UVJO are often considered as congenital obstructive uropathy (COU) phenotypes, whereas bladder dysfunction and PUV are conditions stratified under lower urinary tract obstruction (LUTO). Depending on their severity and/or co-occurrence of other perturbations in development, all of the above mentioned diagnoses can lead to significant morbidity and mortality after birth¹⁰⁻¹², and the potential requirement for early surgical interventions to prevent progression of kidney failure¹³. Genetics has the potential to aid in the ascertainment of diagnosis, prognosis and treatment of COU patients^{2,14}. However, despite the fact that COU is a common human developmental defect, its molecular etiology remains largely elusive¹⁵. Notwithstanding a clear familial occurrence for COU phenotypes, genetic discoveries of monogenic causes or copy number variants (CNV, i.e. large deletions or duplications within the genome) lag behind when compared to other congenital anomalies of the kidney and

urinary tract (CAKUT) such as kidney hypodysplasia^{14,16,17}. One major explanation is that relatively small and heterogeneous cohorts of individuals with COU have been subjected to genetic testing until now^{2,14,18}. Nevertheless, our current genetic knowledge for COU shows strong overlap with other CAKUT phenotypes, as Mendelian forms caused by rare pathogenic single nucleotide variants (SNVs) or genomic disorders caused by pathogenic CNVs have both been identified in individuals with COU as well as congenital kidney hypodysplasia^{16,17,19,20}. As such, this hallmark of variable expressivity within the complex etiology of CAKUT may hamper our ability to ascertain risk and prognosis, thus resulting in suboptimal clinical management and genetic counseling of patients.

In this study, we aimed to elucidate the genetic etiology of upper urinary tract obstruction by performing a large clinical genomic screen of individuals with UPJO, UVJO and congenital hydronephrosis not otherwise specified (COU-NOS), by using a combined approach of exome sequencing for single nucleotide variants (SNVs) and copy number variation (CNV) analysis. Given the common embryonic background of a disturbed outgrowth of the ureteric bud, we hypothesize that the genetic backgrounds of COU subcategories display strong molecular overlap.

METHODS

Study participants

The study involving human subjects was conducted in accordance with the Declaration of Helsinki. All participants and/or guardians provided written informed consent, and the study was approved by the Institutional Review Board (IRB) of Columbia University Irving Medical Center (CUIMC) and the local ethics committees of participating recruitment sites.

The COU study participants consisted of 733 unrelated and affected individuals recruited from 24 participating sites in 7 countries, Italy (n=296), Poland (n=204), Macedonia (n=118), United States (n=61), Croatia (n=47), The Netherlands (n=4), and Turkey (n=3). Diagnosis was based on the ICD10 –code provided by the recruiting physician. The inclusion criteria included individuals who have been clinically ascertained for UPJO, UVJO or COU-NOS. Individuals with a primary hierarchical

diagnosis of other CAKUT phenotypes including kidney anomaly (KA), duplicated collecting system, vesicoureteral reflux (VUR), horseshoe kidney/ectopic kidney (HK-EK) and LUTO/PUV, in isolation or in addition to COU were excluded, as well as individuals with neurogenic obstructive uropathy (e.g. spina bifida) or non-neurogenic neurogenic bladder. 21,498 population controls with available DNA microarray data describe in our prior publication were used for comparisons of CNV frequencies^{16,17,19-22}. An in-house 11,818 multiethnic population controls dataset from the Institute for Genomic Medicine (IGM) was used for allelic frequency estimation of our prioritized SNVs²³.

Exome sequencing, variant and base calling

Genomic DNA was isolated from whole blood according to standard protocols. Proband-only exome sequencing was performed at three sequencing facilities using either the Illumina Hiseq2500 sequencing platform (Yale Mendelian Genomics Center, YMGC; Columbia Institute for Genomic Medicine, IGM) or the Illumina HiseqX10 sequencing platform (New York Genome Center), on the following capture kits: IDT Exome Enrichment Panel, Agilent V4, and Roche NimbleGen SeqCap Exome EX v3.0. The DRAGEN v3 platform was utilized to map sequenced reads to the reference genome (hs37d5.fa, Ensembl -GRCh37.73), GATK 3.6 was subsequently used for base quality recalibration, indel realignment and variant calling. ClinEff was used for variant annotation with Ensembl (version GRCh38), EVS-v.0.0.30, ExAC 0.3²⁴, gnomAD Exome and gnomAD Genome version 2.1²⁵, dbNSFP 4.1a, HGMD 2021.4, Clinvar 2022-01-10²⁶, ACMG v3, and REVEL 2016-06-03. Resulting variant calls, sample-level site coverages data and annotations were stored in the ATAV centralized database and queried²³.

Variant-level quality control and prioritization

We first used a manually curated list of 625 nephropathy-associated genes²⁷, from which we further prioritized 382 genes that, when mutated, are known to cause Mendelian forms of isolated or syndromic CAKUT (**Supplementary Table S1**).

Variants-level data from the 733 COU individuals within the 382 prioritized genes were queried using the variant annotation function implemented in the Analysis Tool for Annotated Variants (ATAV)²³, the analysis variant engine that powers our exome-genome sequencing warehouse (**Supplementary Figure S1**). Variant filtering was performed to require a quality score > 50, quality by depth score >= 2, genotyping quality score >=20, mapping quality score >=40, coverage >= 10, alternate read percentages was within the range of 0.3 and 0.7 for heterozygous genotypes. To further ensure the removal of sequencing artifacts, variants that occurred >=20 within the COU cohort and variants that appeared >=500 within the internal ATAV controls cohort were removed. For variant prioritization, we used the Diagnosticator (<https://diagnosticator.com>) and Varsome (<https://varsome.com/>) web-based platforms that implement the American College of Medical Genetics (ACMG) guidelines²⁸ as a first-pass screen to predict an ACMG verdict for each uploaded variant for further clinical variant interpretation and genotype-phenotype correlation for all 382 genes. We used the following criteria to define a positive genetic finding for our clinical research variant adjudication. First-tier positive findings were considered if the genotype was already reported as pathogenic or likely pathogenic in ClinVar²⁶ or classified as pathogenic or likely pathogenic by strict ACMG criteria via individual variant curation in Varsome. Since missense variants and variants never observed in public databases such as gnomAD rarely meet ACMG P/LP criteria and are often classified as US (unknown significance), in order to define our second-tier positive genetic finding we used the following criteria: absent or exceedingly rare in public databases as well as in our in-house 11,818 multiethnic population controls from the Institute for Genomic Medicine (IGM)²³; a Revel score >=0.5²⁹; plausibility of the genetic mutation to be associated to the observed COU phenotype. Additionally, variants with the PVS1 classifier (i.e. null variant in a gene where loss-of-function is a known mechanism of disease) were classified as positive findings even if other criteria were not fulfilled. We next confirmed prioritized variants through Sanger sequencing in the patient DNA and, when available, in family members for segregation analysis in order to add support to our pathogenicity adjudication.

Exome CNV calling and prioritization

For robust analysis of CNV using exome sequencing data, we first divided our COU exome-sequencing (ES) cohort into four batches grouped by exome-capture kits. GATK DepthOfCoverage (v3.6) and exome Hidden Markov Model,XHMM (v1.0) were used for exome CNV discovery³⁰. CNVs were called based on hg19 coordinates. For each batch, we computed coverage statistics from the base-recalibrated and indel realigned, “analysis-ready” bam files restricting coverage computations to the exome-captured intervals in each kit. Raw coverages were merged, outlier targets and samples were removed, and mean centered-data were normalized with PCA to construct a normalized read depth for CNV calling. A subset of 434 COU cases have also been analyzed using chromosomal microarray data. The identification of pathogenic genomic disorders in 162 out of these 434 individuals has been previously published(**Supplementary Figure S1**)¹⁶. The DNA array CNV calls were detected using PennCNV as described^{16,17,19-21}, and the results used for comparison, calibration, and validation of the exome CNV calls. After DNA array and exome-based CNV analysis we used the bedtools intersect function to compare the putative start and end breakpoints of the XHMM-derived CNV against the putative start and end breakpoints of the PennCNV-derived CNV as an orthogonal method to test for congruency. CNVs were annotated with overlapping RefGenes, Known CNVs with reported association with a genomic disorder and curated gene sets. Using the same criteria for CNV prioritization as previously described, CNVs were classified as “pathogenic” (GD-CNV) or “likely pathogenic”^{16,17,19-22}. Burden of rare CNVs and pairwise comparisons were conducted using Fisher’s exact or Chi Square, as appropriate.

RESULTS

Study cohort

The total cohort included 733 independent COU cases, of whom 321 (43.8%) individuals had UPJO, 178 (24.2%) had UVJO, and 234 (31.9%) individuals were diagnosed with COU-NOS (**Table 1**). The majority of cases were of European ancestry (599, 81.7%; **Supplementary Figure S2**). There was a strong male predominance in COU cases (male 502 (68.5%) vs female 231 (31.5%)). Additional kidney and urinary

tract defects were present in 123 (16.7%) cases, of which reflux nephropathy was most prevalent (6.4% of cases). Extrarenal phenotypes were identified in 127 (17.3%) COU-cases, with abnormalities in musculoskeletal system (n=18, 2.5%), central nervous system (n=14, 1.9%) and cardiac defects (n=19, 2.6%) as predominant conditions. One in five patients had a family history of kidney disease, which was higher in cases with COU-NOS than in individuals with UPJO or UVJO (**Table 1**; OR 2.74, 95% confidence interval (CI) 1.91 – 3.92; Fisher's exact *P*-value = 3.1×10^{-8} vs combined group of UPJO/UVJO).

Exome sequencing identifies rare pathogenic SNVs in 7.2% of COU cases

We queried ES data for 382 manually-curated genes in 733 COU cases using ATAV (**Supplementary Table S1, Supplementary Figure S1**)²³. Of these 382 genes known to be associated to CAKUT when mutated, 127 were associated with dominant inheritance (119 autosomal and 8 X-linked), 240 with recessive inheritance (225 autosomal, 1 digenic, and 14 X-linked), and 15 genes associated with both dominant and recessive inheritance (10 autosomal, 5 X-linked). We retrieved 8,525 raw variants from the ATAV database and annotated them using Diagnosticator. After standard quality control, 1,677 variants were removed. Additional 1,181 variants were further removed because affecting non coding regions (ex 5' or 3' UTR) or classified as “Benign”, “Likely Benign” or “Benign/Likely Benign” in ClinVar at the time of analysis. We next analyzed the remaining 5,667 variants based on the reported mode of inheritance for all CAKUT disorders associated with the genes. To further prioritize rare variants, we removed variants with more than 0.05% minor allele frequency and more than 1% allele frequency for dominant and recessive genes, respectively, in all populations from the public repositories ExAC²⁴ and gnomAD v2.1.1 genomes²⁵. Finally, we individually curated the remaining variants using Diagnosticator and VarSome as decision support tools and applied the first- and second- tier criteria to adjudicate positive findings as described above. Finally, we identified positive genetic findings in 53 (7.2%) COU cases. Of these, 40 (75.4%) individuals had an autosomal dominant genetic cause of COU, 6 (11.3%) individuals harbored pathogenic SNVs in genes with an autosomal dominant or recessive mode of inheritance, and 7 (13.2%) individuals had

an autosomal recessive form of COU, demonstrating a significantly skewed distribution towards genes with an autosomal dominant mode of inheritance in our study cohort. Comparison of COU subcategories did not reveal statistically significant differences in proportions of identified disease-associated SNVs between the three diagnosis groups (Chi square 2x3, $P = 0.57$; **Figure 1**). An overview of all identified SNVs is summarized in **Table 2**.

When zooming in at the contribution of each single gene to the etiology of COU, we identified a striking genetic heterogeneity (33 distinct genes affected in 53 cases) with only a handful of genes harboring pathogenic variants in more than one individual (**Table 2**). The latter included *TNXB* (n=6), *HNF1B* (n=4), *TBX18* (n=3), *PAX2* (n=2), *ALDH18A1* (n=2) and *TP63* (n=2). Genes with an autosomal dominant mode of inheritance predominantly encoded for transcription factors or proteins with a pivotal role in transcription (13/30, 43%; e.g. *HNF1B*, *PAX2*, *TBX18*, *SALL1*, *EYA1*, *FOXC1*, *BMP4*, *BMP7* and others). Interestingly, variants in these genes were identified across all three COU sub-phenotypes, indicating the highly variable expressivity within the genetic etiology of urinary tract malformations, and suggesting that, at least for a fraction of genes involved in COU etiology, the underlying sub-phenotype has no predictive value for the underlying molecular cause. Other important subgroups of autosomal dominant genes known to be associated with COU encode signaling molecules that play a role in multiple developmental processes and cell fate decisions, such as *BRAF*, *NOTCH2* and *SHH*³¹⁻³³. This is in contrast with the variants found in genes with an autosomal dominant/recessive or autosomal recessive mode of inheritance, where the molecular action of genes was much more heterogeneous, including genes that encode for extracellular matrix proteins (*TNXB*, *FREM1*)^{34,35}, muscle proteins (*MYH11*)³⁶, nuclear factors (*SDCCAG8*)³⁷, and transmembrane proteins (*DYNC2H1*)³⁸. In addition to the aforementioned genetic pleiotropy of genes underlying the different COU phenotypes, we observed mutations in *TNXB* mostly in cases with COU-NOS (4 out of 5 individuals). As variants in *TNXB* have been previously predominantly associated to VUR^{35,39}, this specific finding most likely reflects the challenging diagnostic interpretation of hydronephrosis and its distinction from VUR when a voiding cystourethrogram (VCUG) has not been performed or available.

Segregation analysis using in a subset of affected cases for whom parental DNA was available for analysis (**Table 2**) identified *de novo* pathogenic SNVs in two cases. In another two individuals with COU, we could establish familial segregation of the variant in affected individuals. Finally, 10 variants were either maternally or paternally inherited from parents with an unknown urinary tract phenotype. Due to the retrospective nature of the study and the different infrastructure at individual recruitment sites, parental DNA was not available for most cases, thus preventing complete assessment of the variants' inheritance patterns in our cohort.

Further annotation of variants identified additional 8 COU cases (UPJO n=3, UVJO n=2, COU-NOS n=3) that carried a heterozygous SNV in 8 distinct genes with an autosomal dominant mode of inheritance that were completely absent in public repositories and were also predicted to be deleterious according to different publicly accessible prediction tools but did not fulfill our first- or second- tier criteria (**Supplementary Table S2**). These 8 SNVs were classified as variants of uncertain significance pending additional genetic or segregation support.

Rare pathogenic CNVs make up the genetic architecture of an additional 3.1% of COU cases

Under the hypothesis that a fraction of the 680 “unsolved” COU cases might be attributable to CNVs associated to genomic disorders, we conducted an exome-wide CNV analysis using GATK DepthOfCoverage and exome Hidden Markov Model (XHMM) using ES data from the entire cohort (**Supplementary Figure S1**). Out of 733 cases, 468 (63.8%) had also an available Illumina DNA microarray that was used to call CNVs as previously described^{16,17,19-22} and results used for cross-validation of the CNV calls from ES. Using this combinatorial approach, we identified 18 distinct genomic disorders in 23 (3.1%) unique COU cases (**Table 3**). When compared to 134 (0.6%) genomic disorders in 21,498 in controls, this represented a highly significant burden excess of GD in COU (OR 5.16, 95% CI 3.14-8.14; Fisher's exact $P = 2.09 \times 10^{-9}$). Similar to what is observed for the SNVs above, the landscape of CNVs showed high genetic heterogeneity with 18 pathogenic CNVs at 15 chromosomal loci in 23 independent COU cases. In fact, we observed only four loci that were copy number

variable in more than one individual: the chr.1q21.1 TAR syndrome region (one deletion and one duplication; both UVJO); the chr.16p13.11 locus (four deletions, one duplication; four UVJO, one COU-NOS); the 17q12 RCAD syndrome region (three deletions; two COU-NOS, one UPJO); and the chr.22q11.2 microdeletion syndrome region (i.e. DiGeorge/Velocardiofacial Syndrome), for which one UVJO case carried a 22q11.2 microdeletion between low-copy-repeats (LCR) B-D, while one individual with UPJO carried a 22q11.2 microdeletion between LCR A-D (**Table 3**). Taken together, these 4 genomic disorders loci explained nearly half (11/23, 47.8%) of the GD carriers in our COU cases. Although cases with UVJO had a higher burden of GD (8/178, 4.5%) as compared to UPJO or COU-NOS cases (9/321, 2.8%; 6/234, 2.6%, respectively), this difference was not statistically significant (Chi Square 2x3, $P = 0.48$; **Figure 1**). Larger sample size cohorts are required to verify if indeed the UVJO subcategory is more frequently caused by GD as compared to the other classes of COU. Interestingly, COU cases were enriched for deletions compared to duplications (16 deletions vs. 7 duplications), implicating reduced gene dosage via haploinsufficiency as the main molecular mechanism that underlies obstructive uropathies.

Additional annotation of CNVs identified 4 microdeletions and 1 microduplication in 5 COU individuals that all were <100 kb in size, intersected with known CAKUT genes in humans or mice, and were completely absent in 21,498 controls (**Supplementary Table S3**). Since these CNVs have not (yet) been linked to a known genomic disorder that includes CAKUT, we defined these additional CNVs as variants of unknown significance.

Importantly, pathogenic CNVs were identified in three individuals with a pathogenic or likely pathogenic SNV or genotype (and vice versa) (**Table 3**), supporting a correct causality attribution in the two independent analyses for the majority of patients. Of these cases carrying a potentially pathogenic SNV as well as a CNV, one subject with UVJO (P74) carried two ultrarare and potentially pathogenic SNVs in *FGFR3* (with a autosomal dominant or recessive mode of inheritance) or *TBX6* (a driver of the CAKUT phenotypes in the chromosome 16p11.2 microdeletion syndrome¹⁶) as well as a 349 kb deletion at the incompletely penetrant chromosome 1q21.1 susceptibility locus for TAR-syndrome. Another subject (P30) with UPJO carried a very rare ClinVar pathogenic

SNV in *TBX18*, a known gene associated to ureter maldevelopment⁴⁰, as well as a 919 kb deletion at chromosome 1q21.1, a locus shown to display incomplete penetrance and variable expressivity⁴¹. Finally, in the last subject, affected by COU-NOS (P04), we identified another very rare SNV in *TBX18* and the typical 1.4 Mb RCAD deletion at chromosome 17q21. Interestingly, these 3 COU cases did not present with a more severe urinary or extra-urinary phenotype as compared to the rest of the cohort. Hence, in order to dissect the exact pathomechanisms leading to COU in these individuals, additional genetic and functional studies need to be performed.

The overall genomic architecture of COU indicates a diagnosis in about one in 10 individuals, identifies both commonalities and differences among COU sub-phenotypes, and supports convergence between SNVs and CNVs on COU genetic drivers

In our cohort of individuals with COU, the diagnostic yield of candidate pathogenic SNVs and CNVs in cases was 73/733 (10.0%) cases (**Figure 1**). As expected, the overall diagnostic yield of 127 individuals with COU and an extrarenal, syndromic, phenotype (30/127 (23.6%)) was much higher than in 606 individuals with isolated, non-syndromic, COU (43/606 (7.1%)) (OR 4.05, 95% CI 2.42 – 6.77; Fisher's exact $P=3.16 \times 10^{-7}$). In contrast, the presence of a positive family history was not different between cases with a genomic diagnosis (16/73, 21.9%) and cases without a genomic diagnosis (148/660, 22.4%; OR 1.03, 95% CI 0.57-1.85; Fisher's exact $P=1.00$). The genomic landscape across COU sub-phenotypes show remarkable overlap in molecular etiologies, but also differences between categories were observed. First, the distribution of the overall diagnostic yield among phenotypes was n=30 (9.4%), n=23 (12.9%) and n=20 (8.6%) for UPJO, UVJO and COU-NOS, respectively (**Supplementary Figure S3**). Comparison between COU phenotypes did not show differences in the distribution of diagnostic yield (2 x 3 Chi-square $P=0.3$). Another example of the overlap between COU-subcategories is the well-known pleiotropic phenotype that is related to haploinsufficiency of *HNF1B*. In fact, we identified pathogenic SNVs in *HNF1B* across all COU-phenotypes. In addition, we detected chr.17q12 microdeletions (*HNF1B* locus) in 2 cases with COU-NOS and 1 case with UPJO. These findings are in accordance

with the fact that the *HNF1B*-related diseases play a role throughout urinary tract development resulting in anomalies across the entire CAKUT spectrum. Convergence of SNV and CNV data also provides remarkable lead points into the potential pathomechanistic pathways of candidate genes for CAKUT. We identified 5 COU cases (4 deletions and one duplication) harboring microdeletions within the chr.16p13.11 locus, encompassing *MYH11*, as well as one case affected by severe bilateral obstructive megaureters, additional urinary tract anomalies and extrarenal developmental defects, with biallelic mutations in this gene. *MYH11* encodes a heavy chain of myosin expressed in the kidney and the musculature of the urinary tract and bladder. Interestingly, recessive mutations in *MYH11* cause megacystis-microcolon-intestinal hypoperistalsis syndrome 2 (MMIHS2, OMIM 619351), in which affected individuals manifest, among other phenotypes, megabladder, dilated ureters and hydronephrosis^{36,42}. Conversely, heterozygous mutations in *MYH11* have been associated to visceral myopathy-2 (VSCM2, OMIM 619350), a less severe form of smooth muscle myopathy with variable phenotypic expression, which also feature urinary tract obstruction^{43,44}. Taken together, our findings support the implication that *MYH11* is a key dosage-sensitive gene in the urinary tract with its expression possibly correlating with the severity of COU.

DISCUSSION

COU is a subcategory of CAKUT that includes highly heterogeneous phenotypes with a variable clinical presentation and a virtually unpredictable outcome. The major reason for this is related to the fact that the molecular architecture of COU is characterized by high genetic heterogeneity, incomplete penetrance and variable expressivity, which both hamper personalized prognostication and treatment, as well as genetic discovery. Our current study incorporates individuals with developmental ureteral defects who have been subjected to a comprehensive genetic screen that includes whole exome sequencing for SNV as well as CNV analyses. In our hands, this genomic evaluation demonstrated a diagnostic yield of 10.0% of cases. Despite restricting our analysis to only upper urinary tract obstruction phenotypes and conducting subgroup investigation, we found significant overlap between COU's genetic background and other CAKUT

phenotypes such as kidney hypodysplasia and VUR^{16,17,19-22,45}. Our findings alone are yet another confirmation that developmental defects of the kidney and urinary tract are part of a spectrum of congenital malformations that, at least in part, arise from similar molecular alteration. This in turn intimates that even with detailed clinical and imaging workup, our ability to predict the underlying genetic defect is marginal. In fact, the strong variable expressivity of these genetic defects underlies the clinical observation that multiple CAKUT phenotypes occur within individual families, and even within the same individual, notwithstanding the fact that all members carry the same genetic mutation⁴⁶⁻⁴⁸. The finding that the molecular aetiology of COU subcategories shows strong similarities is important because the exact clinical definition of COU phenotypes, and CAKUT at large, is often challenging. Therefore, if our capability to ascertain diagnosis, prognosis, and treatment at the individual level is currently limited, this observed genetic heterogeneity and variable expressivity of COU legitimize a “genetic first” diagnostic approach to these developmental defects, even when extensive (and potentially burdening) clinical and imaging characterization is not completely available or uniform. The same therefore might be true for genetic discovery studies: while there is an obvious value to obtain detailed clinical phenotyping for studies targeted at specific CAKUT subcategories, the aggregation of large cohort of kidney and urinary tract defects at large is likely to lead to the identification of novel susceptibility genes and variants that predispose to CAKUT in its more broad manifestations. Our study also demonstrates that the genetic architecture of COU is likely less well-defined and more complex as compared to other CAKUT subgroups. In fact, congenital kidney anomalies usually show a higher yield of pathogenic SNVs and CNVs⁴⁹⁻⁵³, indicating a “more Mendelian” nature of kidney parenchymal defects as compared to ureteric conditions. One explanation for this observation can be traced back to selective pressure: while kidney malformations significantly affect early life morbidity and mortality and hence are likely to be enriched in highly deleterious mutations that are classified as pathogenic in a clinical genetic diagnostic framework, COU, showing more variable and, on average, more benign course, is likely to be characterized by a more complex genetic determination. Another explanation for this difference with other CAKUT subgroups is the fact that not all COU phenotypes originated from aberrant urinary tract

development by definition, as for example UPJO may also be caused by ectopic vasculature compression or dynamic dysfunction of the ureteral smooth muscle cells⁵⁴. In our cohort, we could not make a clear distinction between these non-developmental causes of COU purely based on clinical and imaging grounds. Although the genomic diagnostic yield is strongly dependent on cohort characteristics and enrolment criteria, our findings are in line with the clinical observation that COU-related phenotypes show different incidence and severity as compared to kidney hypodysplasia⁵⁵. In this study we provide evidence that, by simultaneously assessing SNVs and CNVs with large effect size, we can deliver a genetic diagnosis in up to one in 10 COU cases. The diagnostic yield should be interpreted in the context of a predictive algorithm to implicate pathogenicity, which, in order to favour accuracy, maybe penalizing for the interpretation of missense variants of variants that escape the clear-cut definition of Mendelian mutations and may incorporate inconsistencies⁵⁶. Our findings particularly indicate that genetic testing has high-yield when extrarenal manifestations are present in individuals with COU, which is in line with recent clinical practice recommendations for genetic testing in CAKUT⁵⁷. At the same time, our study points out that a molecular etiology cannot be identified in about 90% of patients. This large unsolved fraction of COU might be attributable to yet undiscovered Mendelian genes or structural variants, common variants with small effect size and a complex polygenic background, low-frequency variants with moderate effect size that are more difficult to assess, and/or a combination of all of the above. Epigenetic, environmental and stochastic factors are also likely to play a significant role. As large sequencing and genotyping efforts are being undertaken, all these different modes of genetic determination will be tested.

AUTHOR CONTRIBUTIONS

Dina Ahram: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – review & editing

Tze Y Lim: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft

Juntao Ke: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft

Gina Jin: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft

Miguel Verbitsky: Conceptualization, Data curation, Methodology, Writing – review & editing

Monica Bodria: Data curation, Writing – review & editing

Byum Hee Kil: Data curation, Writing – review & editing

Debanjana Chatterjee: Data curation, Writing – review & editing

Stacy E Piva: Data curation, Writing – review & editing

Maddalena Marasa: Data curation, Writing – review & editing

Jun Zhang: Data curation, Writing – review & editing

Enrico Cocchi: Data curation, Writing – review & editing

Gianluca Caridi: Data curation, Writing – review & editing

Zoran Gucev: Data curation, Writing – review & editing

Vladimir J Lozanovski: Data curation, Writing – review & editing

Isabella Pisani: Data curation, Writing – review & editing

Claudia Izzi: Data curation

gianfranco savoldi: Data curation, Writing – review & editing

Barbara Gnutti: Data curation

Valentina P Capone: Data curation, Writing – review & editing

William Morello: Data curation, Writing – review & editing

Stefano Guarino: Data curation, Writing – review & editing

Pasquale Esposito: Data curation, Writing – review & editing

Sarah Lambert: Data curation, Writing – review & editing

Jai Radhakrishnan: Data curation, Writing – review & editing

Gerald Appel: Data curation, Writing – review & editing

Natalie Uy: Data curation, Writing – review & editing

Maya Rao: Data curation, Writing – review & editing

Pietro Canetta: Data curation, Writing – review & editing

Andrew Bomback: Data curation, Writing – review & editing

Jordan Nestor: Data curation, Writing – review & editing

Thomas Hays: Data curation, Writing – review & editing

David Cohen: Data curation, Writing – review & editing
Carolina Finale: Data curation, Writing – review & editing
Joanna Wijk: Data curation, Writing – review & editing
Claudio La Scola: Data curation, Writing – review & editing
Olga Baraldi: Data curation, Writing – review & editing
Francesco Tondolo: Data curation
Dacia Di Renzo: Conceptualization
Anna Jamry-Dziurla: Conceptualization
Alessandro Pezzutto: Data curation, Writing – review & editing
Daniele Alberti: Data curation
Valeria Manca: Data curation, Writing – review & editing
Adele Mitrotti: Data curation, Writing – review & editing
Domenico Santoro: Data curation, Writing – review & editing
Giovanni Conti: Data curation, Writing – review & editing
Marida Martino: Data curation, Writing – review & editing
Mario Giordano: Data curation, Writing – review & editing
Loreto Gesualdo: Data curation, Writing – review & editing
Lada Zibar: Data curation, Writing – review & editing
GIUSEPPE MASNATA: Conceptualization
Mario Bonomini: Data curation, Writing – review & editing
Gaetano La Manna: Data curation, Writing – review & editing
Yasar Caliskan: Data curation, Writing – review & editing
Andrea RAnghino: Conceptualization
Krzysztof Koryluk: Data curation, Writing – review & editing
Pierluigi Marzuillo: Conceptualization
Grażyna Krzemień: Data curation, Writing – review & editing
Monika Miklaszewska: Data curation, Writing – review & editing
Fangming Lin: Data curation, Writing – review & editing
Giovanni Montini: Data curation, Writing – review & editing
Francesco Scolari: Data curation, Writing – review & editing
Enrico Fiaccadori: Data curation, Writing – review & editing

Adela Arapović: Data curation, Writing – review & editing
Marijan Saraga: Data curation, Writing – review & editing
James McKiernan: Data curation, Writing – review & editing
Shumyle Alam: Data curation, Writing – review & editing
Marcin Zaniew: Data curation, Writing – review & editing
Maria Szczepanska: Data curation, Writing – review & editing
Agnieszka Szmigielska: Data curation, Writing – review & editing
Przemyslaw Sikora: Data curation, Writing – review & editing
Dorota Drożdż: Data curation, Writing – review & editing
Malgorzata Mizerska Wasiak: Data curation, Writing – review & editing
Shrikant Mane: Data curation, Writing – review & editing
Richard P Lifton: Methodology, Writing – review & editing
Velibor Tasic: Data curation, Writing – review & editing
Anna Latos-Bielenska: Data curation, Writing – review & editing
Ali Gharavi: Conceptualization, Investigation, Methodology, Supervision, Writing – review & editing
Gian Marco Ghiggeri: Conceptualization, Data curation, Writing – review & editing
Anna Materna-Kiryluk: Data curation, Writing – review & editing
Rik Westland: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing
Simone Sanna-Cherchi: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing.

ACKNOWLEDGEMENTS

We thank all patients and family members for participation in this study.

DISCLOSURES

E. Cocchi reports Research Funding: American Society of Nephrology. Z. Gucev reports Consultancy: Novo Nordisk; Advisory or Leadership Role: Novo Nordisk; and Speakers Bureau: Takeda. S. Guarino reports Speakers Bureau: Ferring. J. Radhakrishnan reports Consultancy: Reistone Biopharma, Sanofi Genzyme, Equillium Bio, Aurinia Pharmaceuticals, Reata Pharmaceuticals, Travers Therapeutics, Angion Biomedica, Ani Pharmaceuticals, Novartis, Goldfinch Bio, Chinook; Research Funding: Travers Therapeutics, Bayer, Goldfinch Bio, Vertex pharmaceuticals; Honoraria: Reistone Biopharma, Sanofi Genzyme, Equillium Bio, Aurinia Pharmaceuticals, Reata Pharmaceuticals, Travers Therapeutics, Angion Biomedica, Ani Pharmaceuticals, Novartis, Goldfinch Bio, Chinook; and Advisory or Leadership Role: Kidney International, Kidney International Reports. G. Appel reports Consultancy: Aurinia, Bristol Myers Squibb, EMD Serono, Genentech, Genzyme-Sanofi, E. Lilly, Merck, Pfizer, Mallinkrodt, Omeros, Achillion, Alexion, Reata, Travers therapeutics, chemocentryx, Glaxo-Smith-Kline, Vertex therapeutics, Novartis, Apellis, Chinook, Arrowhead; Research Funding: Sanofi-Genzyme, Mallinkrodt, Reata, Genentech-Roche, Chemocentryx, achillion-alexion, Apellis, Goldfinch, Novartis, Equillium; Honoraria: Aurinia, Glaxo Smith Kline; Patents or Royalties: UpToDate; Advisory or Leadership Role: UpToDate - Editorial Board, Med Advisory board for Alexion, BM Squib, Roche, Genentech, Sanofi, Reata, Aurinia, Lilly, Apellis, Alexion-Achillion, Glaxo-Smith -Kline, Chinook, Arrowhead; and Speakers Bureau: Aurinia - lectures on Lupus Nephritis, GSK - lectures on Lupus Nephritis. P. Canetta reports Consultancy: Otsuka, Travers, Chinook, Novartis; and Research Funding: Calliditas, Travers, Novartis. A. Bomback reports Consultancy: Chemocentryx, Novartis, Otsuka, Silence Therapeutics, Visterra, Catalyst, Q32, Apellis; and Honoraria: UpToDate, Travers, Novartis, Principio, Alexion, Aurinia, Calliditas, Glaxo Smith Kline. D. Cohen reports Consultancy: Alexion - International aHUS Registry - Scientific

Advisory Board; Research Funding: Natera, CSL Behring; Honoraria: ITB Pharmaceuticals, Veloxis, Novartis; Advisory or Leadership Role: Alexion - aHUS International Registry - Scientific Advisory Board; and Other Interests or Relationships: American Society of Transplantation – member, The Transplantation Society – member, NY Society of Nephrology - member. D. Santoro reports Honoraria: Alexion, Trave Therapeutics, Viphor Pharma, Fresenius; and Advisory or Leadership Role: George Clinical. L. Gesualdo reports Consultancy: SANDOZ, SANOFI, BAXTER, MUNDIPHARMA, ESTOR, PHARMADOC, RETROPHIN, TRAVERE, ASTRAZENECA, GSK, NOVARTIS, CHINOOK, ROCHE, MEDTRONIC; Research Funding: ABIONYX, SANOFI; Honoraria: FRESENIUS, ESTOR, WERFEN, ASTELLAS, ASTRAZENECA, TRAVERE; Patents or Royalties: McGraw-Hill Education (Italy) Srl; and Advisory or Leadership Role: NDT Journal, Journal of Nephrology, Board of Directors (SIN, RPS, ERA-EDTA). L. Zibar reports Honoraria: Medison Pharma, and Servier. M. Bonomini reports Consultancy: Astellas; Research Funding: Iperboreal Pharma, Hexal; Advisory or Leadership Role: GSK, Trave Therapeutics; and Speakers Bureau: Astellas, and Nipro. G. La Manna reports Consultancy: Alexion, Astellas, Eli-Lilly, Hansa-Biopharma, Vifor, and Trave therapeutics. A. Ranghino reports spouse works in Diatech Pharmacogenetics s.r.l. K. Kiryluk reports Consultancy: Calvariate, HiBio; and Research Funding: AstraZeneca, Vanda, Bioporo, Aevi Genomics, Visterra. M. Miklaszewska reports Honoraria: Medycyna Praktyczna - Pediatria. F. Lin reports Honoraria: lectures and seminars in academic institutions; and Advisory or Leadership Role: JASN editorial board. G. Montini reports Consultancy: Bayern, Alnylam, Kiowa Kylin, Chiesi Farmaceutici, Sandoz; and Advisory or Leadership Role: Bayern, Alnylam. E. Fiaccadori reports Consultancy: Astellas, Nipro, BBraun, Astra Zeneca; and Other Interests or Relationships: Member Italian Society of Nephrology, Member European Society of Parenteral & Enteral Nutrition. M. Zaniew reports Honoraria: Alnylam. M. Szczepanska reports Research Funding: FMS in Zabrze, SUM in Katowice; Honoraria: Swixx, Roche, Baxter; and Other Interests or Relationships: ESPN, ERA-EDTA, Polish Society for Pediatrics, Polish Society for Pediatric Nephrology. D. Drozd reports Research Funding: Roche. M. Mizerska-wasiak reports Other Interests or Relationships:

European Society Pediatric Nephrology- member, European Renal Association-European Dialysis Transplantation Association -member. A. Gharavi reports Consultancy: Astra Zeneca Center for genomics research, Goldfinch Bio: Actio biosciences, Novartis: Travere; Ownership Interest: Actio; Research Funding: Renal Research Institute, Natera; Honoraria: Sanofi, Alnylam; and Advisory or Leadership Role: Editorial board: JASN and Journal of Nephrology. R. Westland reports Research Funding: Dutch Kidney Foundation (20C002). S. Sanna-Cherchi reports Research Funding: NIH/NIDDK, DoD; Honoraria: Travere Therapeutics; and Advisory or Leadership Role: Editorial Boards with No royalties. S. Lambert reports Ownership Interest: stock in Abbvie and Abbott. D. Ahram reports Employer: Quest Diagnostics. D. Chatterjee reports Employer: H.C. Wainwright & Co., and Citibank; and Patents or Royalties: spouse has a patent with Columbia University Medical Center, not with any for-profit Company. R. Lifton reports Consultancy: Genentech; Ownership Interest: Roche, Merck; and Advisory or Leadership Role: Roche Board of Directors, and Genentech Board of Directors. J. Mckiernan reports Consultancy: miR Scientific; and Advisory or Leadership Role: miR Scientific. All remaining authors declared no competing interests.

Because Ali Gharavi is an editor of the Journal of the American Society of Nephrology, he was not involved in the peer review process for this manuscript. A guest editor oversaw the peer review and decision-making process for this manuscript.

FUNDING

This work was supported by grants (P20 DK116191, RO1 DK103184, and R01 DK115574) from the National Institutes of Health/NIDDK (to SSC) and a consortium grant 20OC002 from the Dutch Kidney Foundation (to RW). Part of the exome sequencing effort was performed by the Yale Center for Mendelian Genomics (YCMG) funded by the National Human Genome Research Institute (U54 HG006504, to RPL).

DATA SHARING STATEMENT

All authors approve adherence to the FAIR data principles. There are some restrictions for this data as follows: Data sharing is possible on the basis of anonymity Exome

sequencing data is available in dbgap submitted as part of the Yale Center for Mendelian Genomics (YCMG)

SUPPLEMENTARY MATERIAL

Supplementary Figure S1. Analytical workflow for SNV and CNV analyses of the study cohort

Supplementary Figure S2. Genetically-determined ancestry proportions of the study cohort

Supplementary Figure S3. Overall diagnostic yield in each COU subcategory

Supplementary Table S1. List of 382 prioritized genes for developmental defects of the kidney and urinary tract (Excel File)

Supplementary Table S2. Ultrarare SNVs of uncertain significance identified in genes with an autosomal dominant inheritance (Excel File)

Supplementary Table S3. Rare structural variants of uncertain significance. (Excel File)

SDC ----<http://links.lww.com/JSN/E403>

SDC Table ----<http://links.lww.com/JSN/E404>

REFERENCES

1. Jackson, A.R., Ching, C.B., McHugh, K.M. & Becknell, B. Roles for urothelium in normal and aberrant urinary tract development. *Nat Rev Urol* **17**, 459-468 (2020).
2. Westland, R., Renkema, K.Y. & Knoers, N. Clinical Integration of Genome Diagnostics for Congenital Anomalies of the Kidney and Urinary Tract. *Clin J Am Soc Nephrol* **16**, 128-137 (2020).
3. Garne, E., Loane, M., Wellesley, D., Barisic, I. & Eurocat Working, G. Congenital hydronephrosis: prenatal diagnosis and epidemiology in Europe. *J Pediatr Urol* **5**, 47-52 (2009).
4. Short, K.M. & Smyth, I.M. The contribution of branching morphogenesis to kidney development and disease. *Nat Rev Nephrol* **12**, 754-767 (2016).
5. Costantini, F. Genetic controls and cellular behaviors in branching morphogenesis of the renal collecting system. *Wiley Interdiscip Rev Dev Biol* **1**, 693-713 (2012).
6. Georgas, K.M. *et al.* An illustrated anatomical ontology of the developing mouse lower urogenital tract. *Development* **142**, 1893-908 (2015).

7. Viana, R. *et al.* The development of the bladder trigone, the center of the anti-reflux mechanism. *Development* **134**, 3763-9 (2007).
8. Capone, V. *et al.* Definition, diagnosis and management of fetal lower urinary tract obstruction: consensus of the ERKNet CAKUT-Obstructive Uropathy Work Group. *Nat Rev Urol* **19**, 295-303 (2022).
9. Khan, K. *et al.* Multidisciplinary approaches for elucidating genetics and molecular pathogenesis of urinary tract malformations. *Kidney Int* **101**, 473-484 (2022).
10. Chesnaye, N.C. *et al.* Survival in children requiring chronic renal replacement therapy. *Pediatr Nephrol* **33**, 585-594 (2018).
11. Wuhl, E. *et al.* Timing and outcome of renal replacement therapy in patients with congenital malformations of the kidney and urinary tract. *Clin J Am Soc Nephrol* **8**, 67-74 (2013).
12. Sanna-Cherchi, S. *et al.* Renal outcome in patients with congenital anomalies of the kidney and urinary tract. *Kidney Int* **76**, 528-33 (2009).
13. Nguyen, H.T. *et al.* The Society for Fetal Urology consensus statement on the evaluation and management of antenatal hydronephrosis. *J Pediatr Urol* **6**, 212-31 (2010).
14. Sanna-Cherchi, S., Westland, R., Ghiggeri, G.M. & Gharavi, A.G. Genetic basis of human congenital anomalies of the kidney and urinary tract. *J Clin Invest* **128**, 4-15 (2018).
15. Avanoglu, A. & Tiryaki, S. Embryology and Morphological (Mal)Development of UPJ. *Front Pediatr* **8**, 137 (2020).
16. Verbitsky, M. *et al.* The copy number variation landscape of congenital anomalies of the kidney and urinary tract. *Nat Genet* **51**, 117-127 (2019).
17. Lopez-Rivera, E. *et al.* Genetic Drivers of Kidney Defects in the DiGeorge Syndrome. *N Engl J Med* **376**, 742-754 (2017).
18. Nicolaou, N. *et al.* Prioritization and burden analysis of rare variants in 208 candidate genes suggest they do not play a major role in CAKUT. *Kidney Int* **89**, 476-86 (2016).
19. Westland, R. *et al.* Copy number variation analysis identifies novel CAKUT candidate genes in children with a solitary functioning kidney. *Kidney Int* **88**, 1402-1410 (2015).
20. Sanna-Cherchi, S. *et al.* Copy-number disorders are a common cause of congenital kidney malformations. *Am J Hum Genet* **91**, 987-97 (2012).
21. Verbitsky, M. *et al.* Copy Number Variant Analysis and Genome-wide Association Study Identify Loci with Large Effect for Vesicoureteral Reflux. *J Am Soc Nephrol* (2021).
22. Verbitsky, M. *et al.* Genomic imbalances in pediatric patients with chronic kidney disease. *J Clin Invest* **125**, 2171-8 (2015).
23. Ren, Z. *et al.* ATAV: a comprehensive platform for population-scale genomic analyses. *BMC Bioinformatics* **22**, 149 (2021).
24. Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285-91 (2016).
25. Karczewski, K.J. *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434-443 (2020).

26. Landrum, M.J. *et al.* ClinVar: public archive of relationships among sequence variation and human phenotype. *Nucleic Acids Res* **42**, D980-5 (2014).
27. Groopman, E.E. *et al.* Diagnostic Utility of Exome Sequencing for Kidney Disease. *N Engl J Med* **380**, 142-151 (2019).
28. Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* **17**, 405-24 (2015).
29. Ioannidis, N.M. *et al.* REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *Am J Hum Genet* **99**, 877-885 (2016).
30. Fromer, M. & Purcell, S.M. Using XHMM Software to Detect Copy Number Variation in Whole-Exome Sequencing Data. *Curr Protoc Hum Genet* **81**, 7.23.1-21 (2014).
31. Gill, P.S. & Rosenblum, N.D. Control of murine kidney development by sonic hedgehog and its GLI effectors. *Cell Cycle* **5**, 1426-30 (2006).
32. Peyssonnaud, C. & Eychene, A. The Raf/MEK/ERK pathway: new concepts of activation. *Biol Cell* **93**, 53-62 (2001).
33. Braley-Mullen, H., Sharp, G.C. & Kyriakos, M. Differential susceptibility of strain 2 and strain 13 guinea pigs to induction of experimental autoimmune thyroiditis. *J Immunol* **114**, 371-3 (1975).
34. Kohl, S. *et al.* Mild recessive mutations in six Fraser syndrome-related genes cause isolated congenital anomalies of the kidney and urinary tract. *J Am Soc Nephrol* **25**, 1917-22 (2014).
35. Gbadegesin, R.A. *et al.* TNXB mutations can cause vesicoureteral reflux. *J Am Soc Nephrol* **24**, 1313-22 (2013).
36. Gauthier, J. *et al.* A homozygous loss-of-function variant in MYH11 in a case with megacystis-microcolon-intestinal hypoperistalsis syndrome. *Eur J Hum Genet* **23**, 1266-8 (2015).
37. Schaefer, E. *et al.* Mutations in SDCCAG8/NPHP10 Cause Bardet-Biedl Syndrome and Are Associated with Penetrant Renal Disease and Absent Polydactyly. *Mol Syndromol* **1**, 273-281 (2011).
38. Badiner, N. *et al.* Mutations in DYNC2H1, the cytoplasmic dynein 2, heavy chain 1 motor protein gene, cause short-rib polydactyly type I, Saldino-Noonan type. *Clin Genet* **92**, 158-165 (2017).
39. Elahi, S. *et al.* Rare variants in tenascin genes in a cohort of children with primary vesicoureteric reflux. *Pediatr Nephrol* **31**, 247-53 (2016).
40. Vivante, A. *et al.* Mutations in TBX18 Cause Dominant Urinary Tract Malformations via Transcriptional Dysregulation of Ureter Development. *Am J Hum Genet* **97**, 291-301 (2015).
41. Mefford, H.C. *et al.* Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. *N Engl J Med* **359**, 1685-99 (2008).
42. Wang, Q. *et al.* Compound heterozygous variants in MYH11 underlie autosomal recessive megacystis-microcolon-intestinal hypoperistalsis syndrome in a Chinese family. *J Hum Genet* **64**, 1067-1073 (2019).

43. Gilbert, M.A. *et al.* Protein-elongating mutations in MYH11 are implicated in a dominantly inherited smooth muscle dysmotility syndrome with severe esophageal, gastric, and intestinal disease. *Hum Mutat* **41**, 973-982 (2020).
44. Dong, W. *et al.* Identification of a dominant MYH11 causal variant in chronic intestinal pseudo-obstruction: Results of whole-exome sequencing. *Clin Genet* **96**, 473-477 (2019).
45. Sanna-Cherchi, S. *et al.* Exome-wide Association Study Identifies GREB1L Mutations in Congenital Kidney Malformations. *Am J Hum Genet* **101**, 789-802 (2017).
46. Munch, J. *et al.* Biallelic pathogenic variants in roundabout guidance receptor 1 associate with syndromic congenital anomalies of the kidney and urinary tract. *Kidney Int* **101**, 1039-1053 (2022).
47. Izzi, C. *et al.* Variable Expressivity of HNF1B Nephropathy, From Renal Cysts and Diabetes to Medullary Sponge Kidney Through Tubulo-interstitial Kidney Disease. *Kidney Int Rep* **5**, 2341-2350 (2020).
48. Sanna-Cherchi, S. *et al.* Mutations in DSTYK and dominant urinary tract malformations. *N Engl J Med* **369**, 621-9 (2013).
49. Ahn, Y.H. *et al.* Targeted Exome Sequencing Provided Comprehensive Genetic Diagnosis of Congenital Anomalies of the Kidney and Urinary Tract. *J Clin Med* **9**(2020).
50. Rasmussen, M. *et al.* Targeted gene sequencing and whole-exome sequencing in autopsied fetuses with prenatally diagnosed kidney anomalies. *Clin Genet* **93**, 860-869 (2018).
51. Heidet, L. *et al.* Targeted Exome Sequencing Identifies PBX1 as Involved in Monogenic Congenital Anomalies of the Kidney and Urinary Tract. *J Am Soc Nephrol* **28**, 2901-2914 (2017).
52. Hwang, D.Y. *et al.* Mutations in 12 known dominant disease-causing genes clarify many congenital anomalies of the kidney and urinary tract. *Kidney Int* **85**, 1429-33 (2014).
53. Weber, S. *et al.* Prevalence of mutations in renal developmental genes in children with renal hypodysplasia: results of the ESCAPE study. *J Am Soc Nephrol* **17**, 2864-70 (2006).
54. Liu, J. *et al.* Crossing vessels with suspension versus transposition in laparoscopic pyeloplasty of patients with ureteropelvic junction obstruction: a retrospective study. *BMC Urol* **21**, 77 (2021).
55. Nishi, K. *et al.* Early predictive factors for progression to kidney failure in infants with severe congenital anomalies of the kidney and urinary tract. *Pediatr Nephrol* (2022).
56. Milo Rasouly, H., Aggarwal, V., Bier, L., Goldstein, D.B. & Gharavi, A.G. Cases in Precision Medicine: Genetic Testing to Predict Future Risk for Disease in a Healthy Patient. *Ann Intern Med* **174**, 540-547 (2021).
57. Knoers, N. *et al.* Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice. *Nephrol Dial Transplant* **37**, 239-254 (2022).

TABLES

Table 1. Study cohort characteristics

Characteristics	UPJO (N = 321)	UVJO (N = 178)	COU-NOS (N = 234)	Overall COU cohort (N = 733)
Gender				
Female	117 (36.4)	51 (28.7)	63 (26.9)	231 (31.5)
Male	204 (63.6)	127 (71.3)	171 (73.1)	502 (68.5)
Laterality				
Bilateral	31 (9.7)	35 (19.7)	64 (27.4)	130 (17.7)
Left	164 (51.1)	95 (53.4)	95 (40.6)	354 (48.3)
Right	94 (29.3)	33 (18.5)	62 (26.5)	189 (25.8)
Unknown	32 (10)	15 (8.4)	13 (5.6)	60 (8.2)
Genetically-determined ancestry				
European participants	264 (82.2)	148 (83.1)	187 (79.9)	599 (81.7)
Admixed participants	40 (12.5)	22 (12.4)	27 (11.5)	89 (12.1)
Hispanic participants	6 (1.9)	5 (2.8)	12 (5.1)	23 (3.1)
South Asian participants	5 (1.6)	2 (1.1)	2 (0.9)	9 (1.2)
African participants	3 (0.9)	1 (0.6)	4 (1.7)	8 (1.1)
East Asian participants	3 (0.9)	0	2 (0.9)	5 (0.7)
Additional renal phenotype				
Bladder defect	2 (0.6)	3 (1.7)	5 (2.1)	10 (1.4)
DCS	8 (2.5)	5 (2.8)	2 (0.9)	15 (2)
Ectopia	5 (1.6)	4 (2.2)	4 (1.7)	13 (1.8)
Glomerular	3 (0.9)	0	2 (0.9)	5 (0.7)
KHD	19 (5.9)	5 (2.8)	7 (3)	31 (4.2)
Nephronopthisis	1 (0.3)	0	0	1 (0.1)
Reflux nephropathy	14 (4.4)	23 (12.9)	10 (4.3)	47 (6.4)
Tubular defect	0	0	1 (0.4)	1 (0.1)
Non-urinary defect				
Neural	8 (2.5)	5 (2.8)	1 (0.4)	14 (1.9)
Craniofacial	8 (2.5)	7 (3.9)	4 (1.7)	19 (2.6)
Cardiac	5 (1.6)	5 (2.8)	9 (3.8)	19 (2.6)
Musculoskeletal	6 (1.9)	8 (4.5)	4 (1.7)	18 (2.5)
Gastrointestinal	6 (1.9)	5 (2.8)	1 (0.4)	12 (1.6)
Genital	12 (3.7)	5 (2.8)	10 (4.3)	27 (3.7)
General Developmental Delay	6 (1.9)	8 (4.5)	4 (1.7)	18 (2.5)
Other syndromes*	0,00	0,00	2 (0.9)	2 (0.3)
Family history of kidney disease	47 (14.6)	35 (19.7)	82 (35)	164 (22.4)

Presented as n (%). * Other syndromes include Currarino syndrome and Beckwith-Wiedemann. COU-NOS, congenital obstructive uropathy – not otherwise specified; DCS, duplex collecting system; KHD, kidney hypodysplasia, UPJO, ureteropelvic junction obstruction; UVJO, ureterovesical junction obstruction.

ACCEPTED

Table 2. Identified rare and potentially pathogenic single nucleotide variants

Autosomal dominant mode of inheritance																
ID	COU Category	Gene	Variant ID	Variant	Consequence	gnomAD Exome global AF	Internal controls AF (N=11,818)	ACMG classification	Clin Var Significance	REVEL Score	Segregation	Gender	FHX (Y/N/U)	Consanguinity (Y/N/U)	Laterality (B/L/R/U)	Additional Genitourinary Phenotype
P75	UVJO	ACTG2	2-74141956-C-T	c.763C>T	p.Arg255Cys	4.04E-06	-	LP	NA	0.937	U	M	N	N	L	
P18	UPJO	ALDH18A1	10-97376235-A-T (rs200452017)	c.1598T>A	p.Leu533Gln	1.37E-04	2.57E-04	US	US	0.915	U	M	N	U	B	
P77	COU-NOS	ALDH18A1	10-97371187-C-G	c.1930G>C	p.Ala644Pro	-	-	US	US	0.652	U	M	U	N	B	
P58	COU-NOS	ARID1B	6-157099426-A-AG	c.189_190insG	p.Gln122AlafsTer110	-	5.68E-04	LB	US	NA	U	M	N	U	L	
P83	UVJO	BMP4	14-54418617-C-CT	c.323dupA	p.Arg109AlafsTer26	-	-	LP	NA	NA	U	F	N	N	U	KHD
P09	UVJO	BMP7	20-55777630-C-	c.661G>A	p.Glu221Lys	-	-	US	NA	0.771	Segregating	M	U	U	R	

			T													
P78	UVJO	<i>BRAF</i>	7-140501356-C-T	c.716G>A	p.Arg239Gln	-	-	US	NA	0.863	Inherited maternal	M	N	U	U	
P36	COU-NO S	<i>COL5A1</i>	9-137711989-G-T	c.4474G>T	p.Gly1492Cys	-	-	P	P	0.994	U	M	N	U	B	Cryptoc hidism
P43	UPJO	<i>DSTYK</i>	1-205180640-C-T	c.24G>A	p.Trp8Ter	-	-	P	P	NA	Segre gatin g	M	N	U	L	N
P34	COU-NO S	<i>EYA1</i>	8-72129030-A-C	c.1239T>G	p.Cys413Trp	-	-	US	NA	0.823	U	M	N	U	R	
P63	UPJO	<i>FOXC1</i>	6-1611089-G-A	c.409G>A	p.Val137Ile	-	-	US	NA	0.621	Pater nal	M	Y	N	R	Double urethra
P56	COU-NO S	<i>GREB1L</i>	18-19019599-G-A	c.949+1G>A	NA	-	-	LP	NA	NA	U	M	N	U	L	
P05	COU-NO S	<i>HNF1B</i>	17-36091625-G-C (rs138986885)	c.1006C>G	p.His336Asp	1.84E-04	3.83E-04	US	Conf lictin g	0.702	Inheri ted mater nal	M	Y	N	R	
P51	UPJO	<i>HNF1B</i>	17-36091625-G-C	c.1006C>G	p.His336Asp	1.84E-04	3.83E-04	US	Conf lictin g	0.702	U	F	N	U	L	

			(rs138986885)													
P79	UPJO	HNF1B	17-36061038-A-T	c.1484T>A	p.Met495Lys	-	-	LP	Conflicting	0.905	U	F	N	U	R	
P66	UVJO	HNF1B	17-36104610-G-A	c.266C>T	p.Pro89Leu	1.61E-05	-	US	NA	0.961	U	M	N	N	L	
P25	UVJO	HNF1B	17-36091633-C-A	c.998G>T	p.Gly333Val	3.99E-06	-	US	NA	0.572	U	M	N	U	B	
P17	UVJO	HOXD13	2-176959349-G-A	c.923G>A	p.Arg308His	3.18E-05	4.23E-05	US	US	0.791	U	M	N	U	L	
P68	UPJO	KAT6B	10-76788346-GTCTA-G (rs199470470)	c.3769_3772delTCTA	p.Lys1258GlyfsTer13	-	-	P	P	NA	U	M	N	N	B	Micropenis, Cryptorchidism, Piriformis bladder
P72	UPJO	KRAS	12-25378651-T-C (rs202247812)	c.347A>G	p.Asn116Ser	-	-	LP	NA	0.878	U	M	N	N	L	
P3	UVJO	MAP2K1	15-66782	c.1163C>G	p.Thr388Ser	-	-	US	NA	0.32	U	F	U	U	B	

1			934-C-G													
P41	UVJO	NFIA	1-61554070-C-T	c.277C>T	p.Leu93Phe	-	4.24E-05	US	NA	0.651	Inherited maternal	F	Y	U	R	
P85	UPJO	NOTCH2	1-120464967-C-T	c.5105G>A	p.Arg1702Gln	7.95E-06	-	US	Conflicting	0.677	U	M	U	N	L	
P24	UPJO	NOTCH2	1-120462920-G-A (rs372061331)	c.5411C>T	p.Ser1804Leu	1.19E-05	4.24E-05	US	NA	0.611	Inherited paternal	F	U	U	B	
P22	COU-NO S	NRI P1	21-16337149-CTTA AA-C	c.3360_3364delTTTAA	p.Asn1120LysfsTer6	-	-	NA	NA	NA	Inherited maternal	M	Y	U	U	Post Infectious Glomerulonephritis
P73	COU-NO S	NSD1	5-176631267-CAGAA-C	c.409_412delGAAA	p.Glu406LysfsTer12	-	-	NA	P	NA	U	F	N	N	B	VUR
P38	UVJO	PAX2	10-102510558-C-T	c.320C>T	p.Pro107Leu	7.95E-06	-	LP	US	0.922	U	M	N	U	B	
P12	UPJO	PAX2	10-102510600-AG-A	c.365delG	p.Gly122AlafsTer37	-	-	LP	NA	NA	De novo	M	N	U	L	VUR

P80	UPJO	PIK3R2	19-18273294-G-A	c.1087G>A	p.Gly363Ser	-	-	US	NA	0.845	U	M	N	U	L	VUR
P03	UPJO	PKD2 [#]	4-88928887-T-A	c.2T>A	p.Met1Lys	3.62E-05	-	LP	NA	0.318	NA	M	U	U	L	
P55	UPJO	RPS24	10-79796953-A-C	c.281A>C	p.His94Pro	-	-	US	NA	0.676	U	F	N	U	L	
P06	COU-NO S	SAL L1	16-51175430-C-T	c.703G>A	p.Ala235Thr	7.96E-06	1.27E-04	US	Conflicting	0.713	Inherited maternal	M	Y	N	R	
P64	UVJO	SHH	7-155599442-AT-A	c.1delA	p.Met1CysfsTer19	-	4.82E-05	LP	NA	NA	U	M	N	U	L	
P61	COU-NO S	SIX5	19-46272101-A-G	c.2T>C	p.Met1?	7.97E-06	-	LP	NA	0.539	U	M	N	U	L	
P21	UVJO	SPECC1L	22-24718863-C-T	c.1915C>T	p.Arg639Ter	-	-	LP	US	NA	De novo	M	N	U	L	VUR
P20	UPJO	TBX18	6-85453979-C-T	c.1004G>A	p.Arg335Lys	-	-	LP	NA	0.565	Inherited paternal	M	N	U	R	
P30*	UPJO	TBX18	6-85446657-G-A	c.1570C>T	p.His524Tyr	8.06E-06	-	US	P	0.757	U	F	U	U	L	

P04*	COU-NO S	TBX18	6-85466546-G-C	c.641C>G	p.Ala214Gly	7.96E-06	-	US	NA	0.53	U	M	N	N	B	VUR, KHD
P42	UPJO	TP63	3-189608591-T-A	c.1666T>A	p.Leu556Met	-	-	US	NA	0.544	U	F	Y	U	B	Solitary kidney
P40	UPJO	TP63	3-189584503-G-A	c.799G>A	p.Val267Ile	1.19E-05	4.24E-05	US	US	0.599	U	M	N	U	L	
Autosomal Dominant or Recessive mode of inheritance																
ID	COU Category	Gene	Variant ID	Variant	Consequence	gnomAD Exome global AF	Internal controls AF (N=11,818)	ACMG classification	Clin Var Significance	REVEL Score	Segregation	Gender	FHX (Y/N/U)	Consanguinity (Y/N/U)	Laterality (B/L/R/U)	Additional Genitourinary Phenotype
P74*	UVJO	FGFR3	4-1808377-G-A (rs104886024)	c.2135G>A	p.Arg712His	-	-	US	NA	0.896	U	M	N	N	U	
P74*	UVJO	TBX6	16-30100037-C-A	c.745G>T	p.Val249Leu	-	-	US	NA	0.943	U	M	N	N	U	
P33	UVJO	TNXB	6-32010285-C-A	c.12157G>T	p.Glu4053Ter	4.01E-06	-	LP	NA	NA	U	M	N	U	R	
P6	UPJO	TNXB	6-32010	c.12134C>T	p.Thr4045Ile	-	-	US	NA	0.564	U	M	Y	U	L	

5			308-G-A													
P82	COU-NO S	TNX B	6-32018039-T-TG (rs34629684)	c.9174dupC	p.Ile3059HisfsTer30	-	-	LP	NA	NA	U	M	Y	N	R	
P57	COU-NO S	TNX B	6-32021490-T-G	c.8468-2A>C	NA	1.23E-05	-	LP	NA	NA	U	F	Y	U	L	
P59	COU-NO S	TNX B	6-32035600-G-A	c.6382C>T	p.Gln2128Ter	-	-	NA	NA	NA	U	M	N	U	B	
P59	COU-NO S	TNX B	6-32057150-CCT-C	c.2363_2364delAG	p.Glu788GlyfsTer18	-	-	NA	NA	NA	U	M	N	U	B	
Autosomal Recessive mode of inheritance																
ID	COU Category	Gene	Variant ID	Variant	Consequence	gnomAD Exome global AF	Internal controls AF (N=11,818)	ACMG classification	Clin Var Significance	REVEL Score	Segregation	Gender	FHX (Y/N/U)	Consanguinity (Y/N/U)	Laterality (B/L/R/U)	Additional Genitourinary Phenotype
P32	UPJO	C5orf42	5-37157912-A-T	c.4511T>A	p.Leu1504Ter	2,39E-05	8,52E-05	NA	P	NA	U	M	N	U	L	
P32	UPJO	C5orf42	5-37226877-TA-T	c.1819delT	p.Tyr607ThrfsTer6	1.61E-04	1.27E-04	NA	P/LP	NA	U	M	N	U	L	
P	CO	DYN	11-	c.2delT	p.Met1Arg	4.03	-	NA	US	NA	Inheri	M	Y	U	L	

07	U-NO S	C2H1	102980304-AT-A		fsTer23	E-06					ted maternal					
P07	COU-NO S	DYN C2H1	11-103175354-G-A	c.11287G>A	p.Ala3763Thr	5.63E-05	1.27E-04	NA	US	0.521	Inherited paternal	M	Y	U	L	
P28	UPJO	FRE M1	9-14842659-C-T	c.1394-1G>A	NA	-	-	NA	NA	NA	U	M	U	U	L	
P28	UPJO	FRE M1	9-14859241-C-T	c.571G>A	p.Gly191Arg	6.09E-04	1.70E-04	NA	Conflicting	0.048	U	M	U	U	L	
P29	UVJO	HPS E2	10-100904148-G-A (rs267606865)	c.457C>T	p.Arg153Ter	1.20E-05	4.24E-05	P	P	NA	U	F	N	U	L	
P50	UPJO	KIAA1109	4-123161006-ATAGTG-A	c.4170_4174delTAGTG	p.Asp1390GlufsTer8	-	-	LP	NA	NA	U	M	N	U	L	
P50	UPJO	KIAA1109	4-123161012-A-C	c.4175A>C	p.Glu1392Ala	-	-	US	NA	0.363	U	M	N	U	L	
P08	UVJO	MYH11	16-15814859-T-G	c.4628A>C	p.Glu1543Ala	3.98E-06	-	US	US	0.918	U	M	N	Y	B	VUR, bladder pseudodiverticuli, hypospa

																dia
P08	UVJO	MYH11	16-15853489-G-A	c.1345C>T	p.Arg449Trp	3.98E-06	-	US	NA	0.742	U	M	N	Y	B	VUR, bladder pseudodiverticuli, hypospadias
P63	UPJO	PKHD1	6-51613307-A-T	c.9107T>A	p.Val3036Glu	-	-	US	Conflicting	0.618	U	M	Y	N	R	
P63	UPJO	PKHD1	6-51924836-G-A (rs376040501)	c.1123C>T	p.Arg375Trp	2.39E-05	4.25E-05	P	P/LP	0.659	U	M	Y	N	R	
P27	UPJO	SDC CAG8	1-243471334-G-T	c.349G>T	p.Glu117Ter	1.19E-05	-	P	P	NA	U	M	N	U	L	
P27	UPJO	SDC CAG8	1-243581270-A-G	c.1310A>G	p.Glu437Gly	-	-	LB	NA	0.114	U	M	N	U	L	

*Individual also carries a genomic disorder. #This individual with a PKD variant was screened and presented one simple cortical cyst at age 32 detected by abdominal CT scan. AF, allele frequency, B, bilateral, COU-NOS, congenital obstructive uropathy – not otherwise specified; F, female; FHx, family history; KHD, kidney hypodysplasia; M, male; (L)P, (likely) pathogenic; N, no; NA, not available; U, unknown; UPJO, ureteropelvic junction obstruction; US, uncertain significance, UVJO, ureterovesical junction obstruction; VUR, vesicoureteral reflux; Y, yes.

Table 3. Identified genomic disorders and likely pathogenic copy number variants

ID	COU Category	CNV	CNV size (Mb)	Type	GD-CNV	Dosage-sensitive genes	CAKUT (Human)	Gender	FHX	Consanguinity	Additional Genitourinary Phenotype	Extrarenal Phenotype
P74*	UVJO	chr1:145415279-145763815	0,349	DEL	1q21.1 susceptibility locus for Thrombocytopenia-Absent Radius (TAR) syndrome		<i>RBM8A</i>	M	N	N		
P84	UVJO	chr1:145415279-145748587	0,333	DUP	1q21.1 TAR Syndrome region duplication		<i>RBM8A</i>	M	N	N	VUR	
P30*	UPJO	chr1:146496480-147415562	0,919	DEL	1q21.1 recurrent microdeletion			F	N	U		
P15	UPJO	chr7:144702944-148544434	3,841	DEL	7q36.1 deletion	<i>CUL1, EZH2</i>		M	U	U		
P26	COU-NOS	chr15:30918893-32404534	1,486	DEL	15q13.3 microdeletion syndrome			F	N	U		
P60	COU-NOS	chr15:23684690-28557995	4,873	DUP	15q11.2 Prader-Willi/Angelman (Type 1) Reciprocal Duplication			M	N	U		
P11	UPJO	chr16:29675050-30199897	0,525	DEL	16p11.2 deletion	<i>PRRT2</i>	<i>TBX6</i>	M	Y	U	VUR, KHD	Bifid thumbs
P44	UVJO	chr16:15460510-17564653	2,104	DEL	16p13.11 recurrent microdeletion	<i>MYH11</i>		M	N	U		
P45	UVJO	chr16:14960412-16357072	1,397	DUP	16p13.11 duplication	<i>MYH11</i>		M	N	U		Preauricular appendix
P67	UVJO	chr16:14947324-16359036	1,412	DEL	16p13.11 recurrent microdeletion	<i>MYH11</i>		M	N	U	LUTM (Phimosi)	Growth retardation
P76	COU-NOS	chr16:15460510-17353355	1,893	DEL	16p13.11 recurrent microdeletion	<i>MYH11</i>		M	N	N		Perthes disease
P04*	COU-NOS	chr17:34851067-36293050	1,442	DEL	RCAD deletion	<i>ACACA, HNF1B</i>	<i>HNF1B</i>	M	N	N	VUR, KHD	
P10	COU-NOS	chr17:34797485-36340198	1,543	DEL	RCAD deletion	<i>ACACA, HNF1B</i>	<i>HNF1B</i>	M	N	N		Facial dysmorphism, Pervasive developmental disorder
P19	UPJO	chr17:34842442-36104994	1,263	DEL	RCAD deletion	<i>ACACA, HNF1B</i>	<i>HNF1B</i>	M	N	U	KHD	
P37	UPJO	chr17:29051270-30377236	1,326	DEL	NF1-microdeletion syndrome	<i>NF1, SUZ12</i>		F	N	U		Neurofibromatosis type I
P46	UVJO	chr22:20706073-21386101	0,680	DEL	DiGeorge A-D, DiGeorge B-D, DiGeorge C-D, DiGeorge C-E			M	Y	U		Mild granular hypospadias, high arched palate, slight antimongoloid slant
P70	UPJO	chr22:18893888-20307511 chr22:20706073-21571022	2,279	DEL	DiGeorge A-B, DiGeorge A-D, DiGeorge C-D, DiGeorge A-D, DiGeorge B-D, DiGeorge C-E	<i>DGCR8</i>		M	N	N		Facial dysmorphism, syndactyly, growth retardation

P47	UPJO	chrX:71693492-72092398	0,399	DUP	Triple X		HDAC8	F	N	U		
P69	UVJO	chrX:149638017-155004401	5,366	DEL	Xq28 Rett syndrome	SLC6A8, MECP2, NSDHL, F8, L1CAM, ABCD1, MTM1, RAB39B, FLNA, DKC1, IKBKG, AVPR2	NAA10, NSDHL, CCNQ, DKC1	F	N	N		Interatrial defect
P54	UPJO	chr2:60679700-66798661	6,119	DUP			WDPCP	F	N	U		
P16	UVJO	chr2:141072471-142888527	1,816	DUP		LRP1B		F	N	U		
P23	UPJO	chr9:137320857-137630692	0,310	DUP			COL5A1	F	N	U		
P52	COU-NOS	chr14:31495110-33293979	1,799	DEL		HECTD1, ARHGAP5, AKAP6		F	Y	U		

*Individual also carries a single nucleotide variant. CAKUT, congenital anomalies of the kidney and urinary tract; COU-NOS, congenital obstructive uropathy – not otherwise specified; CNV, copy number variants, DEL, deletion; DUP, duplication; GD, genomic disorder; F, female; FHX, family history; KHD, kidney hypodysplasia; M, male; N, no; RCAD, renal cysts and diabetes; U, unknown; UPJO, ureteropelvic junction obstruction; UVJO, ureterovesical junction obstruction; VUR, vesicoureteral reflux; Y, yes.

FIGURE LEGENDS

FIGURE 1. Diagnostic yield of genomic screen in 733 individuals with congenital obstructive uropathy. Differences between COU sub-groups for diagnostics SNV and CNV yield were all $P > 0.05$ by using 2x3 Chi square test. A) The overall *in-silico* diagnostic yield of candidate pathogenic SNV and CNV in the COU cohort is 10.0% (73 of 733 patients). This proportion of genomic contribution to the etiology of COU is in accordance with other congenital kidney and urinary tract phenotypes. B) Distribution of COU cases carrying candidate pathogenic/likely pathogenic SNVs based on mode of inheritance. SNVs in genes with an autosomal dominant mode of inheritance were vastly predominant for all COU subtypes. C) Distribution of genomic disorders, likely pathogenic CNVs, and candidate microdeletions and microduplications covering known genes in COU exome cases. As pathogenic deletions were much more frequently found than duplications in all COU subtypes, our data implicates that haploinsufficiency or dominant negative effects are the main molecular mechanisms leading to congenital obstructive uropathy.

AD, autosomal dominant; AR, autosomal recessive; COU, congenital obstructive uropathy; CNV, copy number variants; Del, deletion; Dup, duplication; NOS, not otherwise specified, SNV, single nucleotide variants, UPJO, ureteropelvic junction obstruction; UVJO, ureterovesical junction obstruction.

